Web Exclusives

Released study results indicate that an interval of ≤50 days from diagnosis to treatment significantly improves outcomes in patients with early-stage lung cancer. Read More ›

Smoking cessation ≥3 weeks prior to lung cancer surgery significantly decreases postoperative complications. Read More ›

In a recent study, researchers identified several factors associated with the development of pneumonitis with therapies targeting non–small-cell lung cancer. Read More ›

The chemistry behind selective KRAS G12C therapies and potential future research avenues were discussed in a recently released journal article. Read More ›

Considerations in first-line and second-line therapy selection in non–small-cell lung cancer without genetic alterations were presented in a recent review article. Read More ›

Although generally mild adverse events are associated with the use of immune checkpoint inhibitors for non–small-cell lung cancer, occasionally serious complications may result. Read More ›

Molecular testing of early-stage non–small-cell lung cancer is recommended after clinical trial results demonstrate osimertinib is effective for patients with EGFR-harboring tumors. Read More ›

A recent review of the various approaches to developing new therapeutic drugs to treat KRAS-harboring tumors also discusses emerging drugs. Read More ›

A retrospective cohort study demonstrates patients with inoperable non–small-cell lung cancer receiving aspirin have improved overall survival compared with patients not receiving aspirin. Read More ›

A recent review of case reports of patients with non–small-cell lung cancer receiving immune checkpoint therapy finds neurologic adverse events are a rare but concerning side effect. Read More ›